Physician profile
Raphael I Agada
NPI 1205835725
$5,536.92
in general payments reported to CMS, 2019-2025
29 companies · $867 in 2025
The $867 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $545 · 2020: $395 · 2021: $804 · 2022: $782 · 2023: $937 · 2024: $1,207 · 2025: $867.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,005 · Education: $6.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,004.56 |
| Education | $6.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,751.29 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $854.05 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $549.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $388.21 | 2022-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $301.24 | 2019-2024 | |
| Novo Nordisk INC | $205.85 | 2021-2023 | Wegovy |
| Merck Sharp & Dohme LLC | $144.35 | 2020-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $142.93 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $131.31 | 2021-2025 | Xifaxan |
| Abbvie INC. | $117.25 | 2023-2025 | Ubrelvy, Qulipta |
| Biohaven Pharmaceuticals, INC. | $116.05 | 2021 | |
| Avanir Pharmaceuticals, INC. | $97.39 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.19 | 2023-2025 | Caplyta |
| Global Blood Therapeutics, INC. | $88.56 | 2020-2022 | |
| Zimmer Biomet Holdings, INC. | $87.58 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $79.53 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.80 | 2024-2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $55.67 | 2024-2025 | Austedo Xr, Austedo Xr |
| Eisai INC. | $49.79 | 2021-2022 | |
| Abbott Laboratories | $36.76 | 2024-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $35.34 | 2021-2025 | Cobenfy |
| Lundbeck LLC | $29.66 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $26.67 | 2021 | |
| Vifor Pharma, INC. | $20.02 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.31 | 2025 | Trintellix |
| Amneal Pharmaceuticals LLC | $18.20 | 2025 | Unithroid |
| Mylan Specialty L.P. | $16.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.45 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.29 | 2024 | Opsumit, Uptravi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raphael Agada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.